Mortality in Patients with Biopsy-proven Giant Cell Arteritis: A South Australian Population-based Study

被引:47
|
作者
Ninan, Jem [1 ]
Anh-Minh Nguyen [3 ]
Cole, Antonia [1 ]
Rischmueller, Maureen [1 ]
Dodd, Thomas [4 ]
Roberts-Thomson, Peter [5 ]
Hill, Catherine L. [1 ,2 ]
机构
[1] Queen Elizabeth Hosp, Rheumatol Unit, Woodville, SA 5011, Australia
[2] Univ Adelaide, Hlth Observ, Woodville, SA, Australia
[3] Dept Hlth, Hlth Stat Unit, Woodville, SA, Australia
[4] SA Pathol, Dept Tissue Pathol, Woodville, SA, Australia
[5] Flinders Med Ctr, Dept Allergy Immunol & Arthrit, Woodville, SA, Australia
关键词
MORTALITY RATE; GIANT CELL ARTERITIS; BIOPSY-PROVEN; TEMPORAL ARTERITIS; POLYMYALGIA-RHEUMATICA; SURVIVAL;
D O I
10.3899/jrheum.101254
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To compare mortality rates and cause of death in patients with biopsy-proven giant cell arteritis (GCA) with those in the general population. Methods. Patients with biopsy-proven GCA were identified from pathology reports of temporal artery biopsies in South Australia, from January 1, 1992, to December 31, 2006. All patients with biopsy-proven GCA were linked to the South Australian Births, Death and Marriage Registry to identify deaths until December 31, 2006. Standardized mortality ratios and relative survival (ratio of observed survival in GCA group to expected survival of general South Australian population, matched by age, sex, and calendar time) were calculated. The cause of death recorded on the death certificate was also documented. Results. There were 225 cases of biopsy-proven GCA (163 women and 62 men). The mean age at diagnosis of GCA was 78.2 years. The mean followup period was 66.2 months (SD 47.1 mo). During the followup period, there were 71 deaths in the GCA group (50 women, 21 men). The standardized mortality ratio was 0.99 (95% CI 0.77-1.25). The relative survival for different followup periods demonstrates that patients with GCA experienced similar mortality to the general population (age-matched and sex-matched). Death from cardiovascular causes (45%) was the most common, followed by infection (17%) and cancer (17%). Infection was a significantly more common cause of death in the first year (chi-squared, p = 0.0002). Conclusion. Our population-based cohort study did not demonstrate any increased mortality risk for patients diagnosed with biopsy-proven GCA. The risk of death from infection early in the disease may be increased. (First Release Aug 15 2011; J Rheumatol 2011;38:2215-17; doi:10.3899/jrheum.101254)
引用
收藏
页码:2215 / 2217
页数:3
相关论文
共 50 条
  • [21] A Nonsynonymous Functional Variant of the ITGAM Gene Is Not Involved in Biopsy-proven Giant Cell Arteritis
    David Carmona, F.
    Serrano, Aurora
    Rodriguez-Rodriguez, Luis
    Castaneda, Santos
    Miranda-Flloy, Jose A.
    Morado, Inmaculada C.
    Narvaez, Javier
    Solans, Roser
    Sopena, Bernardo
    Mari-Alfonso, Begona
    Unzurrunzaga, Ainhoa
    Ortego-Centeno, Norberto
    Blanco, Ricardo
    de Miguel, Eugenio
    Hidalgo-Conde, Ana
    Martin, Javier
    Gonzalez-Gay, Miguel A.
    JOURNAL OF RHEUMATOLOGY, 2011, 38 (12) : 2598 - 2601
  • [22] Large vessel involvement in biopsy-proven giant cell arteritis: incidence, distribution, and predictors
    Naderi, N.
    Mohammad, A. J.
    Turesson, C.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2017, 46 (03) : 215 - 221
  • [23] Seasonal variation in biopsy-proven giant cell arteritis in Eastern Denmark from 1990-2018
    Konig, Elisabeth Bay
    Stormly Hansen, Michael
    Foldager, Jonathan
    Siersma, Volkert
    Loft, Annika
    Terslev, Lene
    Moller Dohn, Uffe
    Radmer Jensen, Mads
    Wiencke, Anne Katrine
    Faber, Carsten
    Hamann, Steffen
    Heegaard, Steffen
    ACTA OPHTHALMOLOGICA, 2021, 99 (05) : 527 - 532
  • [24] Clinical features in patients with permanent visual loss due to biopsy-proven giant cell arteritis
    Font, C
    Cid, MC
    CollVinent, B
    LopezSoto, A
    Grau, JM
    BRITISH JOURNAL OF RHEUMATOLOGY, 1997, 36 (02): : 251 - 254
  • [25] Anterior ischemic optic neuropathy due to biopsy-proven giant cell arteritis in Thai patients
    Attaseth, Taweevat
    Vanikieti, Kavin
    Poonyathalang, Anuchit
    Preechawat, Pisit
    Jindahra, Panitha
    Wattanatranon, Duangkamon
    CLINICAL OPHTHALMOLOGY, 2015, 9 : 1071 - 1075
  • [26] Incidence and predictors of thoracic aortic damage in biopsy-proven giant cell arteritis
    Koster, M. J.
    Crowson, C. S.
    Labarca, C.
    Warrington, K. J.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2021, 50 (03) : 239 - 242
  • [27] Giant Cell (Temporal) Arteritis With Anterior Ischemic Optic Neuropathy: A Biopsy-proven Case in Taiwan
    Cheng, Cheng-Kuo
    Lee, Chin-Cheng
    Huang, Kai-Han
    Wu, Tzu-En
    Peng, Pai-Huei
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2010, 109 (07) : 550 - 554
  • [28] Baseline Characteristics and Clinical Presentation of Biopsy-Proven Giant Cell Arteritis in White Compared with Black Patients
    Sun, Emily
    Li, Ximin
    Gruener, Anna M.
    Chang, Jessica R.
    Henderson, Amanda D.
    Carey, Andrew R.
    JOURNAL OF NEURO-OPHTHALMOLOGY, 2023, 43 (04) : 504 - 508
  • [29] Interferon-gamma gene microsatellite polymorphisms in patients with biopsy-proven giant cell arteritis and isolated polymyalgia rheumatica
    Gonzalez-Gay, MA
    Hajeer, AH
    Dababneh, A
    Garcia-Porrua, C
    Amoli, MM
    Llorca, J
    Ollier, WER
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2004, 22 (06) : S18 - S20
  • [30] Seasonal incidence of biopsy-proven giant cell arteritis: a 20-year retrospective study of the University of California Davis Medical System
    Gokoffski, K. K.
    Chatterjee, A.
    Khaderi, S. K.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2019, 37 (02) : S90 - S97